Distalmotion logo

Distalmotion

Distalmotion is a Lausanne, Switzerland, maker of DEXTER, a small, mobile soft-tissue surgical robot aimed at ambulatory surgery centers. It has raised about $400 million and passed 3,000 procedures.1,4

Robotics Reviewed Editorial TeamUpdated November 2, 2026distalmotion.com

Our take

Distalmotion is betting that robotic surgery's next growth comes from ambulatory surgery centers, not hospitals. DEXTER is small enough to wheel between rooms, uses single-use wristed instruments, and works with the laparoscopic cameras and tools a center already owns.3,4

The approach is credible and well funded, with about $400 million raised and a $70 million loan facility from Perceptive Advisors in 2026. The weak points are scale and price transparency: the company has passed 3,000 procedures, a small number next to the market leader, and publishes no system price.4,5

Scores by criterion

Distalmotion scores out of 10
Pricing transparency3.0
Product maturity7.0
Deployment evidence6.0
Company durability7.0
Ease of integration7.5
Overall score (average of the five)6.1

Each criterion is defined on our methodology page.

Who uses Distalmotion and what it's for

DEXTER is cleared in the US for inguinal hernia repair, gallbladder removal, and hysterectomy, with further gynecology and ventral hernia filings in progress, and carries a CE mark in Europe for urology, gynecology, and general surgery.4

Its US sales focus on ambulatory surgery centers, including centers affiliated with HonorHealth, SCA, and Surgery Partners. Cypress Surgery Center in Wichita, Kansas, bought a DEXTER in March 2026 after finding the market leader's system too costly and too bulky for its rooms.3,4

DEXTER

DEXTER pairs a sterile surgeon console, which lets the surgeon step to the bedside at any time, with patient-side arms on a mobile footprint. Distalmotion says it fits any size operating room without modifications and integrates with existing visualization and instruments.3

Chief executive Greg Roche told MD+DI the design targets the constraints of outpatient centers: room size, staffing, and sterile processing capacity.5

Funding and scale

Distalmotion raised $150 million in a Series G in 2025, with Johnson & Johnson's venture arm as a strategic investor, and Roche puts total funding at about $400 million. In 2026 it added a senior secured term loan of up to $70 million.4,5

Roche said the company surpassed 3,000 cumulative procedures in the fourth quarter of 2025 and that the first quarter of 2026 was its best yet.4

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for patients and clinicsTop rated, for large hospitalsLower score, for patients and clinicsLower score, for large hospitalsNot yet reviewed45678910Review Score← Patients and clinicsLarge hospital systems →Who it's built for6.16.56.46.35.8
Distalmotion (DEXTER) and its competitors
CompanyProductPricing modelDeployment footprintWhere Distalmotion wins or loses
Distalmotion (DEXTER)DEXTER soft-tissue surgical robot with a small, mobile footprint3Not published1More than 3,000 cumulative procedures in Europe and the US; focus on ASCs4Built for ASCs; prices not published
Intuitive (da Vinci)da Vinci multi-port and single-port surgical systems8Sales plus leases, many with usage-based payments8About 12,094 systems installed at September 30, 20268Intuitive wins on installed base and range of procedures. Distalmotion wins on a smaller, mobile system for ASCs.
CMR Surgical (Versius)Versius Plus modular surgical robot9Not published; Stryker to act as US sales agent2245,000 cases worldwide; no dedicated OR required9CMR wins on case volume and Stryker's US reach. Distalmotion wins on a design built for ASCs.
MedtronicHugo robotic-assisted surgery system10Not published10FDA cleared in December 2025 for urologic procedures10Medtronic wins on scale and hospital relationships. Distalmotion wins on an ASC-focused footprint.
SS InnovationsSSi Mantra modular surgical robot12Less than a third of a da Vinci's price in a 2022 report13224 systems in twelve countries by June 30, 2026; not yet FDA cleared14,15SS Innovations wins on low price and system count in India. Distalmotion wins on US clearances.
MMI (Medical Microinstruments)Symani robot for open microsurgery on vessels and nerves17Not published; about 900,000 euros reported in 202018About 50 systems installed and 3,500 procedures16MMI wins on open microsurgery on tiny vessels and nerves. Distalmotion wins on soft-tissue surgery in ASCs.
Moon SurgicalMaestro bedside assistant with ScoPilot AI camera control23Not published20FDA cleared in 2024; dataset of more than 3,000 procedures19,23Distalmotion wins on a lightweight telerobot for ambulatory sites. Moon wins on working with the surgeon at the bedside.

Limits

Distalmotion publishes no system or per-procedure price, so the cost advantage it claims cannot be checked without a quote.3

US clearances cover a short list of procedures so far, which limits how many surgeons in a center can use the robot.4

Revenue is not disclosed. We estimate it at $25 million to $45 million a year, based on more than 3,000 procedures, a team of over 150 people, and a third-party estimate of about $45 million. This is an estimate, not a reported figure.2,4

What customers say

Where it helps

Cynthia Meaux, market CEO of Cypress Surgery Center, said robotics was necessary for its program to grow but the economics had always been a barrier, and that with DEXTER the model finally makes sense.3

Steven Schwaitzberg, chairman of surgery at the University at Buffalo, is quoted by the company saying a robotics program in an outpatient facility without disrupting workflows is a game changer.1

Where it falls short

We found no independent cost studies of DEXTER programs. Buyers should ask for instrument cost per case and service terms, since single-use instruments shift spending from sterilization to supplies.3

Leadership

  • Greg Roche

    Greg Roche

    Chief executive officer

    Roche joined as CEO in December 2023 after running Avateramedical and leading robotics at Zimmer Biomet, where he launched the ROSA knee system.6

    Read full profile

Sources

  1. Distalmotion, Homepage, accessed November 2, 2026
  2. Distalmotion, About us, accessed November 2, 2026
  3. Distalmotion, Distalmotion accelerates US commercial momentum in ASCs, May 21, 2026, accessed November 2, 2026
  4. MedTech Dive, Surgeries are moving to ASCs. Distalmotion wants its robot to drive the shift., accessed November 2, 2026
  5. MD+DI, Why ASCs need robots built for them, not retrofitted from hospitals, accessed November 2, 2026
  6. DeviceTalks Boston, Greg Roche speaker profile, accessed November 2, 2026
  7. Distalmotion, Distalmotion raises $150 million, November 18, 2025, accessed November 1, 2026
  8. Intuitive Surgical, Form 10-Q for the quarter ended September 30, 2026, accessed November 1, 2026
  9. CMR Surgical, Home page, accessed November 1, 2026
  10. Medtronic, FDA clearance of Hugo robotic-assisted surgery system, December 3, 2025, accessed November 1, 2026
  11. Medtronic, Sphere-9 and PulseSelect registry results, October 22, 2026, accessed November 1, 2026
  12. SS Innovations, Investor overview, accessed November 1, 2026
  13. Business Standard, SSI Mantra costs one-third of global price, September 15, 2022, accessed November 1, 2026
  14. SS Innovations, Second quarter 2026 financial results, August 13, 2026, accessed October 31, 2026
  15. SS Innovations, Response to FDA request for additional information on the SSi Mantra 510(k), October 13, 2026, accessed October 31, 2026
  16. MMI, Series D announcement, October 8, 2026, accessed November 2, 2026
  17. MMI, Homepage, accessed November 2, 2026
  18. CNBC, Symani microsurgery robot, October 28, 2020, accessed November 2, 2026
  19. Sofinnova Partners, Moon Surgical receives second FDA clearance, covering its commercial Maestro surgical robotics system, June 4, 2024, accessed November 3, 2026
  20. Moon Surgical, Homepage, accessed November 3, 2026
  21. PR Newswire, Moon Surgical and KARL STORZ announce strategic commercial collaboration, July 22, 2026, accessed November 3, 2026
  22. CMR Surgical, Stryker and CMR Surgical announce strategic alliance, October 12, 2026, accessed November 2, 2026
  23. PR Newswire, Moon Surgical expands Maestro platform into a multi-model physical AI platform with software version 2.7, June 9, 2026, accessed November 3, 2026